언어 선택

PSGL-1

PSGL-1 분자 정보

영어 이름	P-selectin glycoprotein ligand-1	시판 약물 수	0
임상 약물 수	4	표적 별명	P-selectin glycoprotein ligand 1，PSGL-1，SELPLG，Selectin P Ligand，Cutaneous Lymphocyte-Associated Associated Antigen，CD162 Antigen，CD162，PSGL1，CLA
최고 연구 개발 단계	Phase 2 Clinical

영어 이름	P-selectin glycoprotein ligand-1
표적 별명	P-selectin glycoprotein ligand 1，PSGL-1，SELPLG，Selectin P Ligand，Cutaneous Lymphocyte-Associated Associated Antigen，CD162 Antigen，CD162，PSGL1，CLA
시판 약물 수	0
임상 약물 수	4
최고 연구 개발 단계	Phase 2 Clinical

PSGL-1 제품 목록

속성
Protein (2)
제품 라이브러리
온라인 (2)
종
Human (2)
태그
His Tag (1)His Tag & Avi Tag (1)
마커
Unconjugated (1)Biotin-labeled (1)

제품 번호	종	발현 시스템	제품 설명	단백질 구조	순도	특성
PS1-H52H9	Human	HEK293	Human PSGL-1 / CD162 Protein, His Tag
PS1-H82E4	Human	HEK293	Biotinylated Human PSGL-1 / CD162 Protein, His,Avitag™

총 수량2

PSGL-1분자 배경

P-selectin glycoprotein ligand 1 (PSGL-1) is also known as Selectin P ligand (SELPLG), CD antigen CD162. PSGL-1 is disulfide-linked homodimer which is the high affinitycounter-receptor for P-selectin on expressed on activated endothelial cells and platelets. PSGL-1 / SELPLG interacts with P-, E- and L-selectins, through their lectin/EGF domains, is required for promoting recruitment and rolling of leukocytes. These interactions require sialyl Lewis X glycan modification but there is a differing dependence for tyrosine sulfations. Dimerization appears not to be required for P-selectin/SELP binding. PSGL-1 can interact with SNX20, MSN and SYK. PSGL-1 / SELPLG mediate the activation of SYK by SELPLG.

PSGL-1분자 별명

PSGL1,CD162,SELPLG,Selectin P ligand

임상 약물 정보

영어 이름	연구 코드	연구 개발 단계	회사	적응증	임상 시험
Cepeprubart	SelK-2	Phase 2 Clinical	Selexys	Asthma; Pulmonary Disease, Chronic Obstructive; Venous Thromboembolism	상세
Leiolizumab	AbGn 168H2; AbGn-268; AbGn-168H2; ALTB-268	Phase 2 Clinical	Altrubio Inc	Arthritis, Psoriatic; Colitis, Ulcerative	상세
Neihulizumab	AbGn-168; AbGn-168H; ALTB-168	Phase 1 Clinical	Altrubio Inc	Arthritis, Psoriatic; Colitis, Ulcerative; Graft vs Host Disease; Plaque psoriasis; Psoriasis	상세
SSGJ-617	SSGJ-617; SSGJ617; 61X; VTX-0811; 617	Phase 1 Clinical	Verseau Therapeutics Inc	Solid tumours	상세